Literature DB >> 21985943

K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs.

Minjmaa Minjgee1, Mahmoud Toulany, Rainer Kehlbach, Klaudia Giehl, H Peter Rodemann.   

Abstract

PURPOSE: It is known that postirradiation survival of tumor cells presenting mutated K-RAS is mediated through autocrine activation of epidermal growth factor receptor (EGFR). In this study the molecular mechanism of radioresistance of cells overexpressing mutated K-RAS(V12) was investigated. METHODS AND MATERIALS: Head-and-neck cancer cells (FaDu) presenting wild-type K-RAS were transfected with empty vector or vector expressing mutated K-RAS(V12). The effect of K-RAS(V12) on autocrine production of EGFR ligands, activation of EGFR downstream pathways, DNA damage repair, and postirradiation survival was analyzed.
RESULTS: Conditioned medium collected from K-RAS(V12)-transfected cells enhanced activation of the phosphatidylinositol-3-kinase-Akt pathway and increased postirradiation survival of wild-type K-RAS parental cells when compared with controls. These effects were reversed by amphiregulin (AREG)-neutralizing antibody. In addition, secretion of the EGFR ligands AREG and transforming growth factor α was significantly increased upon overexpression of K-RAS(V12). Expression of mutated K-RAS(V12) resulted in an increase in radiation-induced DNA-dependent protein kinase catalytic subunit (DNA-PKcs) phosphorylation at S2056. This increase was accompanied by increased repair of DNA double-strand breaks. Abrogation of DNA-PKcs phosphorylation by serum depletion or AREG-neutralizing antibody underscored the role of autocrine production of EGFR ligands, namely, AREG, in regulating DNA-PKcs activation in K-RAS mutated cells.
CONCLUSIONS: These data indicate that radioresistance of K-RAS mutated tumor cells is at least in part due to constitutive production of EGFR ligands, which mediate enhanced repair of DNA double-strand breaks through the EGFR-phosphatidylinositol-3-kinase-Akt cascade.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21985943     DOI: 10.1016/j.ijrobp.2011.05.057

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  29 in total

Review 1.  [Experimental tumor therapy].

Authors:  M Baumann; D Zips; M Krause
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

2.  ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.

Authors:  Mahmoud Toulany; Minjmaa Minjgee; Mohammad Saki; Marina Holler; Friedegund Meier; Wolfgang Eicheler; H Peter Rodemann
Journal:  Cancer Biol Ther       Date:  2013-12-09       Impact factor: 4.742

Review 3.  Reversion of the ErbB malignant phenotype and the DNA damage response.

Authors:  E Aaron Runkle; Hongtao Zhang; Zheng Cai; Zhiqiang Zhu; Barry L Karger; Shiaw-Lin Wu; Donald M O'Rourke; Zhaocai Zhou; Qiang Wang; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2012-09-27       Impact factor: 3.362

4.  Muc1 knockout potentiates murine lung carcinogenesis involving an epiregulin-mediated EGFR activation feedback loop.

Authors:  Xiuling Xu; Wenshu Chen; Shuguang Leng; Mabel T Padilla; Bryanna Saxton; Julie Hutt; Mathewos Tessema; Kosuke Kato; Kwang Chul Kim; Steven A Belinsky; Yong Lin
Journal:  Carcinogenesis       Date:  2017-06-01       Impact factor: 4.944

5.  Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.

Authors:  Meng Wang; Jing Han; Lynnette Marcar; Josh Black; Qi Liu; Xiangyong Li; Kshithija Nagulapalli; Lecia V Sequist; Raymond H Mak; Cyril H Benes; Theodore S Hong; Kristin Gurtner; Mechthild Krause; Michael Baumann; Jing X Kang; Johnathan R Whetstine; Henning Willers
Journal:  Cancer Res       Date:  2017-02-15       Impact factor: 12.701

6.  Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader
Journal:  World J Exp Med       Date:  2012-04-20

7.  Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab.

Authors:  Nicholas G Zaorsky; Yunguang Sun; Zixuan Wang; Joshua Palmer; Paolo M Fortina; Charalambos Solomides; Maria Werner-Wasik; Adam P Dicker; Rita Axelrod; Barbara Campling; Nathaniel Evans; Scott Cowan; Bo Lu
Journal:  Cancer Biol Ther       Date:  2013-08-02       Impact factor: 4.742

8.  Epidermal growth factor receptor-dependent DNA repair promotes murine and human hematopoietic regeneration.

Authors:  Tiancheng Fang; Yurun Zhang; Vivian Y Chang; Martina Roos; Christina M Termini; Lia Signaevskaia; Mamle Quarmyne; Paulina K Lin; Amara Pang; Jenny Kan; Xiao Yan; Anna Javier; Katherine Pohl; Liman Zhao; Peter Scott; Heather A Himburg; John P Chute
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

9.  Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer.

Authors:  Gaurab Chakrabarti
Journal:  Radiat Oncol       Date:  2015-07-16       Impact factor: 3.481

Review 10.  Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity.

Authors:  Luqing Zhao; Ann M Bode; Ya Cao; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-07-12       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.